{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:56:42Z","timestamp":1783738602439,"version":"3.55.0"},"reference-count":22,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Historically, sickle cell disease (SCD) has been overshadowed by progress in other hematologic disorders, but recent advances are reshaping its clinical and research landscape. Despite SCD reducing life expectancy by &amp;gt;20 years even with optimal care, transformative initiatives are fostering hope for improved outcomes. The American Society of Hematology (ASH) established the ASH Research Collaborative Sickle Cell Disease Research Network as a comprehensive program to revolutionize SCD research in the United States. This Network comprises a collection of innovative, research-focused cooperative sites and a robust Data Hub that aggregates extensive real-world data sets to enhance clinical insights and streamline research designs. Community advisory boards at both local and national levels ensure that the perspectives of individuals living with SCD guide research priorities. This report includes an overview of the initial demographics, such as the number of records, encounters, laboratory data, prescriptions, years of follow-up, and comorbidities per patient, within the context of the ASH Research Collaborative Sickle Cell Disease Research Network. These coordinated efforts are poised to significantly transform the landscape of SCD care, and this report details the initiative\u2019s mission, history, achievements to date, and its promising trajectory toward improving the lives of individuals affected by this chronic condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016394","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:00:09Z","timestamp":1756926009000},"page":"48-57","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["The ASH Research Collaborative Sickle Cell Disease Research Network: past, present, and future"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8583-0526","authenticated-orcid":false,"given":"Fuad","family":"El Rassi","sequence":"first","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biree","family":"Andemariam","sequence":"additional","affiliation":[{"name":"2Department of Medicine, New England Sickle Cell Institute, University of Connecticut Health, Farmington, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5482-8087","authenticated-orcid":false,"given":"Abdullah","family":"Kutlar","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1275-4112","authenticated-orcid":false,"given":"Betty S.","family":"Pace","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliza","family":"Fink","sequence":"additional","affiliation":[{"name":"5ASH Research Collaborative, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Torres","sequence":"additional","affiliation":[{"name":"5ASH Research Collaborative, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dowd","sequence":"additional","affiliation":[{"name":"5ASH Research Collaborative, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Abrams","sequence":"additional","affiliation":[{"name":"6Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"issue":"8","key":"2026011308563251400_bib1","doi-asserted-by":"crossref","first-page":"E558","DOI":"10.1016\/S2352-3026(23)00169-2","article-title":"Sickle cell disease: time to act on the most neglected global health problem","volume":"10","author":"Osei","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026011308563251400_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-3-319-06713-1_3","volume-title":"Sickle Cell Anemia: From Basic Science to Clinical Practice","author":"Steinberg","year":"2016"},{"issue":"1","key":"2026011308563251400_bib3","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"2026011308563251400_bib4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2026011308563251400_bib5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"2026011308563251400_bib6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"2026011308563251400_bib7","first-page":"319","article-title":"Treatment of severe forms of sickle cell anemia with bone marrow allograft: French experience (15 cases)","volume":"35","author":"Bernaudin","year":"1993","journal-title":"Nouv Rev Fr Hematol"},{"issue":"6","key":"2026011308563251400_bib8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJM199608083350601","article-title":"Bone marrow transplantation for sickle cell disease","volume":"335","author":"Walters","year":"1996","journal-title":"N Engl J"},{"issue":"18","key":"2026011308563251400_bib9","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"2026011308563251400_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ajh.26741","article-title":"Lovo-cel gene therapy for sickle cell disease: treatment process evolution and outcomes in the initial groups of the HGB-206 study","volume":"98","author":"Kanter","year":"2023","journal-title":"Am J Hematol"},{"key":"2026011308563251400_bib11","unstructured":"Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA\u00ae (Voxelotor) From Worldwide Markets. Pfizer. 2024. Accessed 10 September 2025. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-voluntarily-withdraws-all-lots-sickle-cell-disease."},{"issue":"12","key":"2026011308563251400_bib12","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/bloodadvances.2020001851","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain","volume":"4","author":"Brandow","year":"2020","journal-title":"Blood Adv"},{"key":"2026011308563251400_bib13","author":"National Academies of Sciences, Engineering, and Medicine","year":"2020"},{"issue":"23","key":"2026011308563251400_bib14","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/bloodadvances.2019000882","article-title":"End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain","volume":"3","author":"Farrell","year":"2019","journal-title":"Blood Adv"},{"issue":"23","key":"2026011308563251400_bib15","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1182\/bloodadvances.2020003434","article-title":"A community-centered approach to sickle cell disease and clinical trial participation: an evaluation of perceptions, facilitators, and barriers","volume":"5","author":"Lee","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"2026011308563251400_bib16","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/cid\/ciw817","article-title":"Combatting global infectious diseases: a network effect of specimen referral systems","volume":"64","author":"Fonjungo","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"4 suppl","key":"2026011308563251400_bib17","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S","volume":"38","author":"Hassell","year":"2010","journal-title":"Am J Prev Med"},{"issue":"23","key":"2026011308563251400_bib18","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1182\/bloodadvances.2021005902","article-title":"ASH Research Collaborative: a real-world data infrastructure to support real-world evidence development and learning healthcare systems in hematology","volume":"5","author":"Wood","year":"2021","journal-title":"Blood Adv"},{"key":"2026011308563251400_bib19","unstructured":"U.S. Department of Health and Human Services\n          . Uses and Disclosures for Research Under Limited Data Sets. Code of Federal Regulations. Accessed 10 September 2025. https:\/\/www.ecfr.gov\/current\/title-45\/subtitle-A\/subchapter-C\/part-164\/section-164.514."},{"key":"2026011308563251400_bib20","unstructured":"U.S. Department of Health and Human Services\n          . Uses and Disclosures for Research Purposes (Including Waiver of Authorization). Code of Federal Regulations. Accessed 10 September 2025. https:\/\/www.ecfr.gov\/current\/title-45\/subtitle-A\/subchapter-C\/part-164\/subpart-E\/section-164.512."},{"key":"2026011308563251400_bib21","unstructured":"Office for Civil Rights (OCR)\n          . Summary of the HIPAA Privacy Rule. U.S. Department of Health and Human Services. Accessed 10 September 2025. https:\/\/www.hhs.gov\/hipaa\/for-professionals\/privacy\/laws-regulations\/index.html."},{"issue":"12","key":"2026011308563251400_bib22","doi-asserted-by":"crossref","first-page":"248","DOI":"10.15585\/mmwr.mm7312a1","article-title":"Birth prevalence of sickle cell disease and county-level social vulnerability - Sickle Cell Data Collection Program, 11 States, 2016-2020","volume":"73","author":"Kayle","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/48\/2478346\/blooda_adv-2025-016394-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/48\/2478346\/blooda_adv-2025-016394-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T13:56:40Z","timestamp":1768312600000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/1\/48\/547096\/The-ASH-Research-Collaborative-Sickle-Cell-Disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016394","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,13]]},"published":{"date-parts":[[2025,12,30]]}}}